In vivo mapping of vascular inflammation using the translocator protein tracer 18F-FEDAA1106 by Cuhlmann, S. et al.
 The University of Bradford Institutional 
Repository 
http://bradscholars.brad.ac.uk 
This work is made available online in accordance with publisher policies. Please refer to the 
repository record for this item and our Policy Document available from the repository home 
page for further information. 
To see the final version of this work please visit the publisher’s website. Access to the 
published online version may require a subscription. 
Link to publisher’s version: http://dx.doi.org/10.2310/7290.2014.00014  
Citation: Cuhlmann S, Gsell W, Van der Heiden K et al (2014) In Vivo Mapping of Vascular 
Inflammation Using the Translocator Protein Tracer 
18
F-FEDAA1106. Molecular Imaging. 13(6): 1-
11. 
Copyright statement: © 2014 Decker Intellectual Properties. This is an Open Access article 
published under the Creative Commons CC-BY license. 
 
 
RESEARCH ARTICLE
In Vivo Mapping of Vascular Inflammation Using the
Translocator Protein Tracer 18F-FEDAA1106
Simon Cuhlmann,* Willy Gsell,* Kim Van der Heiden, Josef Habib, Jordi L. Tremoleda, Magdy Khalil,
Federico Turkheimer, Merlijn J. Meens, Brenda R. Kwak, Joseph Bird, Anthony P. Davenport, John Clark,
Dorian Haskard, Rob Krams, Hazel Jones, and Paul C. Evans
Abstract
Noninvasive imaging methods are required to monitor the inflammatory content of atherosclerotic plaques. FEDAA1106 (N-(5-fluoro-
2-phenoxyphenyl)-N-(2-(2-fluoroethoxy)-5-methoxybenzyl) acetamide) is a selective ligand for TSPO-18kDa (also known as peripheral
benzodiazepine receptor), which is expressed by activated macrophages. We compared 18F-FEDAA1106 and 2-deoxy-2-[18F]fluoro-D-
glucose (18F-FDG, a marker of glucose metabolism) for positron emission tomographic (PET) imaging of vascular inflammation. This
was tested using a murine model in which focal inflammation was induced in the carotid artery via placement of a constrictive cuff.
Immunostaining revealed CD68-positive cells (macrophages) at a disturbed flow site located downstream from the cuff. Dynamic PET
imaging using 18F-FEDAA1106 or 18F-FDG was registered to anatomic data generated by computed tomographic (CT)/CT
angiography. Standardized uptake values were significantly increased at cuffed compared to contralateral arteries using either
18F-FEDAA1106 (p , .01) or FDG (p , .05). However, the 18F-FEDAA1106 signal was significantly higher at the inflamed disturbed flow
region compared to the noninflamed uniform flow regions, whereas differences in FDG uptake were less distinct. We conclude that
18F-FEDAA1106 can be used in vivo for detection of vascular inflammation. Moreover, the signal pattern of 18F-FEDAA1106
corresponded with vascular inflammation more specifically than FDG uptake.
A THEROSCLEROSIS is a chronic inflammatory diseaseof the arterial wall. The degree of inflammation and the
presence of macrophages are believed to influence the risk of
plaque rupture.1 Thus, noninvasive methods to monitor the
inflammatory content of plaques are required for the clinical
management of patients with cardiovascular disease.
We recently developed a novel imaging method to study
the effects of altered blood flow on vascular function in living
animals that involves coupling of positron emission tomo-
graphic (PET) imaging with the generation of spatially
distinct blood flow fields in murine carotid arteries.2 The
method involves surgical placement of a cuff manufactured
from polytetrafluoroethylene (PTFE) on the carotid artery.
The cuff has an internal diameter of 500 mm tapering to
250 mm over a length of 1 mm, thus altering the geometry of
the vessel lumen. We demonstrated that the altered geometry
of cuffed arteries corresponds to altered patterns of blood
flow. Specifically, the cuff generates regions of high uniform
(at the cuff), low uniform (upstream), and disturbed
(downstream) blood flow.3,4 Using this model, we pre-
viously demonstrated that vascular inflammation occurs
specifically at the downstream disturbed flow site and that
uptake of 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG, an
analogue of glucose) is enhanced at this region.2 However,
although PET-FDG is widely used to assess vascular
inflammation,5–8 it remains an unspecific marker. Indeed,
uptake of FDG can be associated with multiple, diverse
processes that involve glucose metabolism, including cell
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division, muscle contraction, overall metabolic activity, and
fibrosis as well as inflammation. Thus, FDG-PET does not
differentiate between glucose uptake due to inflammation and
the uptake due to other metabolic processes in adjacent
tissues. This problem is exemplified during analysis of FDG
uptake in inflamed carotid arteries and thoracic aortas, which
can be affected by spillover of uptake in brain and heart,
respectively, due to their high metabolic activity. It is thus of
primary importance to develop new imaging biomarkers that
identify inflamed regions of arteries more specifically.
During the late 1980s, tracers binding to benzodiaze-
pine receptors in the brain were also found to interact with
the outer mitochondrial membrane. They were originally
referred to as peripheral benzodiazepine receptors because
of their high expression in peripheral organs such as
adrenal glands and kidneys9 but are now termed
translocator protein 18 kDa (TSPO).10 TSPO is highly
expressed in macrophages11,12 and therefore may be a
suitable target for imaging inflammation. Numerous TSPO
PET tracers have been developed and used mainly for the
imaging of neuroinflammation.13,14 Recent publications
have demonstrated the potential use of TSPO tracers as a
surrogate marker of vascular inflammation.15–18 The aim
of the present study was to examine whether the TSPO
tracer 18F-FEDAA1106 can be used to image vascular
inflammation in vivo and to compare the specificity of 18F-
FEDAA1106 and 18F-FDG for imaging of inflammation.
Methods
Animals
Male C57BL/6 mice or apolipoprotein E–deficient mice
(ApoE2/2; C57BL/6 background) between 2 and 4 months of
age were used. Constrictive cuffs with an internal diameter of
500 mm tapering to 250 mm over a length of 1 mm were
manufactured from PTFE. They were placed on the right
carotid artery under isoflurane anesthesia as previously
described.3,4 All experiments were carried out according to
the guidelines laid out in the Animals Scientific Procedures
Act (1986) under a project license from the UK Home Office
and approved by the local ethical review panel following
guidelines from the Geneva University Animal Care and Use
Committee in accordance with Swiss regulations.
Radioprobes
18F-FDG was provided by Siemens PETNET Solutions
(Mount Vernon Hospital, UK). N-(5-fluoro-2-phenoxy-
phenyl)-N-(2-18F-fluoroethyl-5-methoxybenzyl) acetamide
(18F-FEDAA1106) and unlabeled FEDAA1106 were kindly
provided by the Wolfson Brain Imaging Centre, University
of Cambridge. Synthesis was performed by radiofluorina-
tion of a tosyl precursor (TsEDAA1106). The [18F]-
FEDAA1106 synthesis concentration range was 0.156
to 0.55 nmol/mL, and the specific activity was 224 to
1,357 GBq/mmol.
In Vivo FDG PET/CT Imaging
A combined PET/computed tomographic (CT) preclinical
scanner was used (Inveon, Siemens Preclinical Solutions,
Munich, Germany). A CT scan was first acquired to correct
PET data for photon attenuation with the power of the x-ray
source set to 80 kVp and 500 mA, 220 projections, and an
exposure time of 200 ms. Three bed positions were acquired
to match the full PET field of view with a final isotropic
resolution of 103 microns. PET acquisition for 1 hour was
initiated simultaneously to intravenous injection of 18F-FDG
(8.9 6 3.6 MBq, n5 5) or 18F-FEDAA1106 (9.1 6 3.4 MBq,
n 5 6), with an energy window of 350 to 650 keV and a
coincidence timing window of 3.4 ns. Finally, the animal
bed was moved back to the center of the CT field of
view prior to CT angiography using Ultravist 370 (Bayer
Healthcare Pharmaceuticals, Leverkusen, Germany), which
was infused intravenously at a speed of 6 mL/hr using a
syringe pump (PHD 22/2000, Harvard Apparatus, Holliston,
MA).2 CT angiography was acquired using the following
parameters: electrocardiography and respiration gating, x-
ray source set to 80 kVp and 500 mA, 220 projections over
220u, and an exposure time of 200 ms.
Image Reconstruction
PET and CT reconstructions were performed using the
Inveon Acquisition Workplace (IAW v1.5, Siemens
Preclinical Imaging). All PET scans were normalized for
detector inhomogeneity and corrected for scatter and
attenuation. Then PET data were assessed over 37 frames
to identify any movement artifacts and were reconstructed
using an iterative approach with a combination of ordered
subset expectation maximization and maximum a poster-
iori (OSEM-MAP) algorithm with two OSEM3D iterations
and 16 subsets, followed by 18 MAP iterations. The
smoothing factor b in MAP reconstructions was set to 0.5.
A matrix of 256 3 256 and a zoom of 2 were applied to all
data during reconstruction, providing a final resolution of
0.215 3 0.215 3 0.796 mm. CT data were reconstructed
using a filtered backprojection–based method modified
from the algorithm of Feldkamp and colleagues19 with no
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down-sampling, a bilinear interpolation, and a Shepp-
Logan filter. Polynomial-based soft tissue beam hardening
correction was applied to the projection data for CT
angiography. Pre- and postcontrast three-dimensional (3D)
volumes were coregistered using rigid body transformation.
Data were then subtracted using an in-house script written
in Matlab 7.0 (MathWorks, Natick, MA) and visualized
using 3D maximum intensity projection in OsiriX 3.9
(OsiriX Imaging Software, Los Angels, CA).
Definition of Regions of Interest and Quantification
Analysis was performed in IRW 4.0 (Siemens Preclinical
Solutions). Briefly, CT, PET, and CT angiography data were
loaded simultaneously and coregistered using adaptive rigid
body transformation (Siemens IRW 4.0). Regions of interest
were defined on CT angiography images and then overlaid
onto PET images to allow quantification of PET signals. Six
regions, each 8 mm3, were studied: on the cuff (high
undisturbed flow) and downstream (rostral; disturbed flow)
and upstream (caudal; low undisturbed flow) on the
ipsilateral (cuffed) and contralateral (unmanipulated) sides.
Standardized uptake values (SUVs) normalized to body
weight were calculated providing a comparable quantifica-
tion (g/mL) for each animal on the summed framed for the
last 15 and 20 minutes for 18F-FEDAA1106 and 18F-FDG,
respectively. CT angiography volumes were segmented
using a Hounsfield unit window of 400 to 700. Right and
left carotid diameters were then determined at the same
level of each region of interest used for the PET analysis.
Arterial Input Function
The arterial input function was derived from the images. A
volume of interest was drawn covering the left ventricle of
the heart. Time-activity curves were then extracted for
voxels with highest activity at early times after injection
(within the first 12 seconds following the injection) and
the lowest activity at the late time point (30–60 minutes
postinjection) to avoid voxels corrupted by the spillover
of the uptake in the surrounding tissues. Typically, the
region of interest for the arterial input function included
90 6 18 voxels.
Nonlinear Least Square Fitting for Kinetic Modeling
Kinetic modeling was achieved using a one–tissue
compartment model. In this model, the kinetic rate
constants K1 and k2 represent the tracer uptake from the
blood pool (Cp) by the tissue (C1) and the elimination
from tissue to blood pool, respectively. The macroscopic
parameter Vt (volume of distribution) was extracted as the
ratio between K1 and k2:
dC1 tð Þ
dt
~K1Cp tð Þ{k2C1 tð Þ
Vt~
K 1
k2
Graphical Analysis
The linearization of reversible binding was achieved using
the technique described by Logan20 implemented under
IRW 4.0 (Siemens Preclinical Solutions). Parameters were
estimated from the following equation:
Ð T
o
CT tð Þdt
CT Tð Þ ~V
Ð T
o
CP tð Þdt
CT Tð Þ zb for Twt

where V represents the Vt after reaching the equilibration
time t*. At t*, V and b were estimated as the slope and
intercept, respectively, using the linear regression form the
time T.t*. In our case, we started the linear regression
with t* set to 30 minutes.
Statistics
The appropriateness of the model was estimated by
computing the Akaike information criterion (AIC):
AIC~n ln
Xn
i~1
wi Yobsi{YCalið Þ2
 
z2p
where n is the number of data points, wi is the weight applied
to the points (Poisson weighting), p is the number of
parameters, Ycal is the value calculated by the model, and Yobs
is the observed data. For graphical methods, the goodness of
fit was estimated using the linear correlation coefficient (R2).
Correlations with R2 , .8 were rejected. Changes between
time-activity curves were assessed using the Mann-Whitney
nonparametric test. Kinetic parameters were compared using
the Wilcoxon signed rank test followed by a paired t-test. Data
are expressed as mean 6 standard error of the mean (*p ,
.05; **p , .01; ***p , .001).
Immunostaining
The accumulation of macrophages at high (at the cuff), low
(upstream), and disturbed (downstream) flow regions was
assessed by en face immunostaining. Animals were perfused
in situ with phosphate-buffered saline and then perfusion
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fixed with 2% formalin prior to the harvesting of carotid
arteries. Fixed vessels were tested by immunostaining using
anti-CD68 antibodies (Serotec, Hercules, CA) and Alexa
Fluor 568–conjugated secondary antibodies. Endothelial
cells were identified by costaining with anti-CD31 anti-
bodies (BD Biosciences Pharmingen, San Jose, CA)
conjugated with fluorescein isothiocyanate (FITC). Cell
nuclei were visualized through a DNA-binding probe with
far-red emission (ToPro3, Invitrogen). Costaining of
TSPO (Abcam, Cambridge, UK, ab 109497; 1:50 dilution)
and MAC3 (macrophage marker; BD Pharmingen; 1:100
dilution) was carried out using frozen cross sections.
Modified arteries were embedded in OCT compound
and snap frozen prior to the preparation of 5 mm thick
sections. Fluorescence was measured in stained vessels using
confocal laser-scanning microscopy (Zeiss LSM 510 META,
Oberkochen, Germany).
Results
18F-FEDAA1106 Binding to TSPO-Rich Tissues
We assessed the specificity of the 18F-FEDAA1106 probe by
studying its ex vivo binding to murine hearts, which are
enriched for TSPO expression. We observed in three
independent experiments that preincubation of tissue
sections with 1 mM unlabeled FEDAA1106 reduced sub-
sequent binding of 18F-FEDAA1106 by 55% (p, .05; Figure
S1, online version only). Moreover, in vivo studies revealed
that 18F-FEDAA1106 signals from the heart were reduced
by 93% following a subsequent injection of unlabeled
FEDAA1106 (2.6 mg/kg; 250 nmol per animal), indicating
that the unlabeled form can displace 18F-FEDAA1106 from
cardiac tissues (Figure S2, online version only). Collectively,
these data indicate that 18F-FEDAA1106 can bind to TSPO-
rich tissues and likely indicate specificity.
18F-FEDAA1106 In Vivo Biodistribution in Mice
The in vivo biodistribution of 18F-FEDAA1106 was studied
in mice with cuffed carotid arteries. PET signals were
quantified in multiple tissues and at particular regions of
right and left carotid arteries using a multimodality
approach in which CT angiography and PET were
coregistered with a CT scan (Figure 1). It was observed
that 18F-FEDAA1106 showed primary elimination through
the kidneys and the liver (Figure 2). The uptake observed
at the level of the lungs and brain appeared to progressively
decrease, whereas the uptake at the level of the carotids
increased. These data indicate that systemically introduced
18F-FEDAA1106 distributes quickly and then washes out
rapidly from tissues through the kidneys and liver.
18F-FEDAA1106 Uptake Was Enhanced at a Site of
Vascular Inflammation
A flow-altering cuff was used to modify murine carotid
arteries to generate spatially distinct sites of vascular
Figure 1. Multimodality approach using CT/PET/CT angiography
data. The right carotid arteries of mice (C57BL/6) were modified using
a constrictive cuff. After 2 weeks, mice were injected intravenously
with 18F-FEDAA1106. CT angiography (A) and FEDAA1106 PET (C)
were coregistered to the CT scan (B). This resulted in a complex image
(PET/CT/CT angiography) (D) in which the cuff (indicated by arrow)
and PET signal can easily be identified. Eight cubic millimeter regions
of interest were drawn on the CT angiography and used to inform
quantitation of PET signals at discrete sites within the carotid arteries.
Data are representative of those obtained from five animals.
Figure 2. 18F-FEDAA1106 dynamic biodistribution at multiple sites.
The right carotid arteries of mice (C57BL/6) were modified using a
constrictive cuff. After 2 weeks, mice were injected intravenously with
18F-FEDAA1106. Time-activity plots are shown for different organs.
Data from six animals were pooled and are expressed as percentage of
injected dose per cubic centimeter (%ID/cc, mean 6 SEM) as a
function of postinjection time (minutes).
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inflammation. In vivo CT angiography enabled clear
localization of the constrictive cuff (Figure 3) and there-
fore the precise location of regions of interests for PET
quantification. Moreover, the 3D rendering enabled us to
visualize the constriction induced on the carotid artery
and, more importantly, to ensure that the cuff was not
placed too close to the vessel bifurcation, which is a site of
endogenous disturbed flow and inflammation. Our study
revealed that the diameter of contrast media associated
with the right carotid (cuffed) was significantly higher than
the diameter at the left carotid artery (unmanipulated) (see
Figure 3E; 1.25 6 0.09 mm vs 0.58 6 0.03 mm,
respectively). This is unlikely to be due to aliasing because
the density of PTFE is very close to water. Instead, we
suggest that a proportion of the contrast medium at the
right carotid artery was extravascular as a signal appeared
to originate from outside the cuff (see Figure 3D,
arrowhead).
To avoid the potential effects of soluble/pooled probe,
we quantified PET signals in carotid arteries using late
frames where the soluble probe had been ‘‘washed out.’’
Using this approach, it was observed that the 18F-
FEDAA1106 signal was significantly higher in the right
compared to the left carotid artery (Figure 4A; 0.72 6 0.15
vs 0.50 6 0.08, respectively, p , .01). When investigating
more precisely the uptake at the level of the carotids, time-
activity curves (Figure 5A) showed a significantly higher
increase in binding at the downstream region (disturbed
flow) when compared to the cuffed or upstream regions
(3.55 6 0.98 vs 2.30 6 0.67 %ID/g for downstream and cuff,
respectively, at 60 minutes postinjection, p , .001, Mann-
Whitney test). This increase in the binding reached a steady
state early after injection (within 2–3 minutes) and remained
constant until the end of the scan (60 minutes). By contrast,
time-activity curves extracted from the brain and lungs
revealed maximum activity at 1 minute postinjection and
then a progressive decrease over time (see Figure 3 and
Figure 5A). Similarly, calculation of SUVs from 45 to 60
minutes post-FEDAA1106 injection demonstrated enhanced
activity at the downstream site (see Figure 4D; 0.9 6 0.18 vs
0.6 6 0.11 [cuffed] and 0.65 6 0.12 [upstream] at 60
minutes postinjection). The estimation of K1, k2, and Vt by
one-compartment analysis and the Vt estimated by the
graphical Logan plot were calculated for carotid arteries (and
for brain as a reference; Table 1). Vt was significantly higher
at the downstream region compared to adjacent sites (0.71 6
0.15 vs 0.43 6 0.10 [cuff] vs 0.41 6 0.081 [upstream]
estimated by non least square fitting (NLS), p , .05). This
result reflects the significant increase in K1 in that region
(0.148 6 0.071 [downstream] vs 0.105 6 0.06 [cuff] vs 0.12
6 0.07 [upstream], p , .001). Although the mean Vt values
estimated by the graphical analysis were larger than those
estimated by compartmental analysis in all regions, a good
correlation was observed between them (r2 5 .998; see
Figure 5B).
En face immunostaining of the lumen of cuffed arteries
revealed that CD68-positive cells accumulated at the
Figure 3. Visualization of carotid arteries using CT angiography. The
right carotid arteries of mice (C57BL/6) were modified using a
constrictive cuff. After 2 weeks, CT scans were performed before (A)
and following (B) intravenous injection of Ultravist 370 contrast agent.
CT angiography allowed localization of the constrictive cuff (arrow) on
the right carotid artery. Pre- and postcontrast CT images were
subtracted (C). The subtracted 3D data were then processed for 3D
rendering (D). Note the accumulation of contrast agent outside the
cuff at the right carotid artery (arrowhead). E, The diameters of
contrast agent associated with the right or left carotid arteries were
measured. Measurements were made at the level of the cuff,
downstream and upstream in the right carotid artery, and at
equivalent positions in the left carotid artery. Data were pooled from
three measurements from each site using five mice, and mean values 6
SEM are shown. Scale bars indicate 1 cm.
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downstream region but not at the upstream or cuffed
region (Figure 6A). There was increased FEDAA1106
binding in regions containing increased CD68-positive
cells (compare Figure 4 to Figure 6A). Moreover,
costaining studies revealed that TSPO was expressed by
macrophages in modified arteries (Figure 6B). Thus, we
conclude that 18F-FEDAA1106 PET can be used to
discriminate between inflamed and noninflamed regions
in experimental arteries.
FDG Uptake at Inflamed and Noninflamed Sites
PET imaging revealed that FDG uptake was enhanced in
the right compared to the left carotid artery (Figure 7A;
1.29 6 0.28 vs 0.71 6 0.10, respectively, p , .05). Analysis
of particular regions of interest in the right carotid artery
revealed that FDG uptake was elevated at the downstream
region compared to adjacent regions (Figure 7, B to D; 1.53
6 0.38 downstream vs 1.29 6 0.32* [cuff] and 1.04 6 0.24*
[upstream]; *p, .05). However, the 18F-FEDAA1106 signal
pattern discriminated between the inflamed (downstream)
region and noninflamed (cuff) regions more effectively than
FDG uptake (compare Figure 4 and Figure 7).
Discussion
Murine models offer several advantages for studies
of vascular inflammation, including the availability of
transgenic/knockout animals, short generation time, and
ease of manipulation and husbandry. However, the small
size of mice presents significant challenges for molecular
imaging studies. We previously attempted PET imaging to
study the spatial distribution of vascular inflammation in
murine arteries, a process that occurs preferentially at
branches and bends that are exposed to disturbed flow.
However, it was not possible to distinguish between
specific sites (eg, aortic arch, ostia of carotid arteries)
because they were closer than the spatial resolution of PET
imaging (approximately 1 mm; data not shown). Because
of these considerations, we developed a novel imaging
system that coupled PET imaging to surgical application of
a constrictive cuff in murine carotid arteries.2 The cuff
generated a site of disturbed flow-induced inflammation
(downstream from the cuff) that could be imaged by PET
as it was spatially separated from adjacent inflammation-
prone regions.
Here we used the constrictive cuff model to compare
binding of a TSPO tracer to uptake of FDG for imaging of
vascular inflammation. The study required a multimod-
ality approach so that the spatial localization of PET
signals could be coregistered with CT angiography data.
CT angiography also suggested that contrast agent was
located outside the cuff in experimental arteries, and we
hypothesize that leakage of cuffed arteries is a conse-
quence of altered blood flow. Our observation has
important implications for the interpretation of PET data
as the bioavailability of the tracer is likely to be altered in
cuffed compared to unmanipulated arteries. For this
reason, comparison of PET signals between distinct
regions of interest within the cuffed artery may have
greater validity than comparing signals between cuffed
and control vessels.
The most extensively studied TSPO tracer is 11C-
PK11195.15,18 In vitro studies demonstrated that PK11195
binds to sites of inflammation in human carotid artery
Figure 4. 18F-FEDAA1106 binding was enhanced at a disturbed flow
region in cuffed arteries. The right carotid arteries of mice (C57BL/6)
were modified using a constrictive cuff. After 2 weeks, mice were
injected intravenously with 18F-FEDAA1106. 18F-FEDAA1106 binding
was studied in the right (cuffed) or the left (unmanipulated) carotid
artery. PET/CT/CT angiography images were coregistered, and
representative composite images are shown in coronal (A) or sagittal
(B, C) orientation. D, 18F-FEDAA1106 binding was quantified at the
cuff and downstream and upstream regions in the right carotid artery
and at equivalent positions in the contralateral carotid artery expressed
as SUVs. Data from six animals were pooled, and mean SUVs 6 SEM
are shown. Scale bars indicate 1 cm.
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Table 1. Non Least Square Fitting and Graphical Analysis Summary.
NLS GA
Region K1 (mL.g–1, min–1) k2 (min–1) Vt (mL/g) AIC Vt (mL/g) R2
Ipsilateral
Cuff 0.105 6 0.060 0.192 6 0.074 0.43 6 0.10 584 6 7 0.51 6 0.11 0.99 6 0.01
Upstream 0.120 6 0.070 0.238 6 0.087 0.41 6 0.08 557 6 15 0.49 6 0.08 0.99 6 0.01
Downstream 0.148 6 0.07*** 0.183 6 0.046 0.71 6 0.15* 571 6 15 0.78 6 0.14** 0.99 6 0.01
Contralateral (control)
Cuff 0.057 6 0.29 0.162 6 0.042 0.31 6 0.08 572 6 13 0.51 6 0.11 0.99 6 0.01
Upstream 0.114 6 0.048 0.305 6 0.080 0.32 6 0.06 537 6 6 0.41 6 0.07 0.99 6 0.01
Downstream 0.108 6 0.066 0.194 6 0.068 0.45 6 0.10 575 6 8 0.52 6 0.10 0.99 6 0.01
Brain 0.177 6 0.079 0.322 6 0.091 0.49 6 0.08 512 6 13 0.56 6 0.07 0.99 6 0.01
AIC 5 Akaike information criterion; GA 5 graphical analysis; NLS 5 non least squares fitting; Vt 5 volume of distribution.
*p , .05; **p , .01; ***p , .001.
Figure 5. Kinetic modeling of 18F-FEDAA1106 binding in experimental arteries. The right carotid arteries of mice (C57BL/6) were modified using
a constrictive cuff. After 2 weeks, mice were injected intravenously with 18F-FEDAA1106. A, Time-activity plots are shown. 18F-FEDAA1106
binding was quantified in right (cuffed) carotid arteries at the cuff and at downstream and upstream regions. Data from six animals were pooled
and are expressed as percentage of injected dose per cubic centimeter (%ID/cc, mean 6 SEM) as a function of postinjection time (minutes). The
downstream region to the cuff elicited a significantly higher activity than the cuff or upstream regions (***p , .001, Mann-Whitney tests). B, Vt
values estimated using the non least squares method were plotted against those generated using the graphical method as a comparison. Each point
represents the average Vt value calculated from each of the regions analyzed. Mean values 6 standard deviations are shown (*p, .05, ***p, .001,
Wilcoxon signed rank test followed by paired t-test).
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plaques.16,17 This probe has also been used successfully to
image vascular inflammation in patients with large vessel
vasculitis.12,18 However, Laitinen and colleagues demon-
strated that PK11195 interacted with both healthy and
diseased arteries in hypercholesterolemic mice, possibly due
to nonspecific binding of PK11195 leading to a poor signal to
background ratio.15 This observation has been supported by
other studies that revealed high uptake of PK11195 in
healthy, noninflamed tissues.21 The quantification of TSPO
probes in general has proved to be very challenging because
of the small amount of specific binding but also the relatively
nonnegligible specific binding to blood vessels.22–24 Because
of these concerns, alternative TSPO probes have now been
developed.17,25,26 These include N-(2,5-dimethoxybenzyl)-N-
(5-fluoro-2-phenoxyphenyl)acetamide (DAA1106), which
colocalized with CD68-positive macrophages in atherosclero-
tic plaques more specifically than PK11195.17
Here we studied a novel TSPO probe, 18F-FEDAA1106,
using a murine model. In vivo biodistribution analyses
of multiple tissues demonstrated that this probe was
distributed rapidly immediately following injection.
Uptake of 18F-FEDAA1106 progressively decreased in lung
and brain, and the probe was eliminated via the kidneys
and liver. These data informed subsequent analyses of 18F-
FEDAA1106 uptake in murine carotid arteries; of parti-
cular note, signals in the carotid arteries were quantified at
late frames when soluble levels of probe were low. Our
observations were broadly similar to an in vivo biodis-
tribution study of 18F-FEDAA1106 in humans, which
Figure 6. TSPO expression corresponded with regions of macrophage
enrichment in cuffed arteries. A, The right carotid arteries of mice
(C57BL/6) were modified using a constrictive cuff. The accumulation
of CD68-positive cells (red) in cuffed arteries was assessed by en face
staining of the lumen at the cuff and at downstream and upstream
regions. Endothelial cells were identified by costaining with anti-CD31
antibodies conjugated to FITC (green). Cell nuclei were identified
using ToPro3 (purple). Representative images are shown. Data were
pooled from three independent experiments, and mean numbers of
macrophages (6 standard deviations) are shown. B, The right carotid
arteries of mice (ApoE2/2) were modified using a constrictive cuff.
After 6 weeks, cross sections of modified carotid arteries were stained
using antibodies that recognize macrophages (MAC3; green) and
TSPO (red) and fluorescent secondary antibodies (left panel). Adjacent
sections were processed in the absence of primary antibodies as a
control for specific staining (right panel). The data shown are
representative of those generated from four mice. Scale bars indicate
20 mm.
Figure 7. 18F-FDG uptake was enhanced at multiple regions of cuffed
arteries. 18F-FDG uptake was studied in the right (cuffed) or the left
carotid artery (unmanipulated). PET/CT/CT angiography images were
coregistered, and representative composite images are shown in
coronal (A) or sagittal (B, C) orientation. D, 18F-FDG uptake was
quantified at the cuff and downstream and upstream regions in the
right carotid artery and at equivalent positions in the contralateral
carotid artery and expressed as SUVs. Data from five animals were
pooled, and mean SUVs 6 SEM are shown. Placement of the flow-
altering, constrictive cuff induced an increase in FDG uptake at the
cuff and at a downstream region. Scale bars indicate 1 cm.
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demonstrated decline of probe uptake from lung and
brain.27 This study also revealed an absence of 18F-
FEDAA1106 signal from carotid arteries and a relatively
low signal in the heart 1.7 hours after intravenous
injection. Thus, it is feasible that clinical protocols could
be developed to image 18F-FEDAA1106 uptake in carotid
or coronary arteries.
To determine whether 18F-FEDAA1106 can be used to
detect vascular inflammation, we compared probe binding
in three regions of cuffed murine carotid arteries in vivo: the
upstream region (noninflamed), the cuff (also noninflamed),
and the downstream region (inflamed). 18F-FEDAA1106
binding at the downstream site was significantly higher than
binding at the nonupstream or cuffed regions, indicating that
binding was associated with vascular inflammation. Thus, the
noninflamed portions of the cuffed artery served as internal
controls for nonspecific binding not associated with
inflammation. Kinetic analyses of the 18F-FEDAA1106 PET
data also demonstrated that the downstream region had
higher K1 values compared to other tissues but similar k2
values, suggesting an increase in binding at this site. It is likely
that the signal at the downstream site was generated by tissue-
bound 18F-FEDAA1106 and that the contribution of soluble/
pooled probe was minimal because (1) PET signals in the
carotid arteries were quantified at late frames when soluble
levels of probe were low; (2) immunostaining demonstrated
that TSPO was expressed by macrophages in cuffed arteries;
and (3) 18F-FEDAA1106 binding in the heart competed with
unlabeled FEDAA and could be displaced by unlabeled
FEDAA1106, likely indicating specificity. Collectively, these
data suggest that elevated FEDAA1106 binding in inflamed
arteries is mediated by enhanced interaction with TSPO
expressed by macrophages.
Although FDG uptake was most pronounced at the
inflamed region, it was also detected at adjacent nonin-
flamed sites, suggesting that the increase in FDG uptake
was not related exclusively to the presence of macrophages
but possibly due to the presence of fibrotic tissue that
developed around the cuff.2 We conclude that 18F-
FEDAA1106 binding has greater specificity for vascular
inflammation compared to FDG uptake because it
corresponded more tightly with the spatial localization of
vascular inflammation in experimental arteries.
Our study relied on alteration of flow in the carotid
artery to establish mechanical conditions that were
permissive for vascular inflammation. This reductionist
approach allowed us to assess the potential utility of 18F-
FEDAA1106 for PET imaging of vascular inflammation in
inflamed arteries in the absence of lipid deposition or the
build-up of other atheromatous materials. Further studies
are now required to monitor 18F-FEDAA1106 binding
during plaque development, to assess the influence of
plaque materials (eg, lipid, calcium, cell debris) on 18F-
FEDAA1106 uptake, and to assess whether 18F-FEDAA1106
can be used to monitor inflammatory load in atherosclerotic
plaques in vivo.
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Figure S1. Specific binding of 18F-FEDAA in mouse tissues. Specific
binding of FEDAA was quantified in mouse heart, a tissue known to
have high, homogeneous expression of TSPO receptor. Tissue sections
were incubated in 18F-FEDAA at a final concentration of 0.05 nM
(total binding) (A). Nonspecific binding was measured in the presence
of 1 mM unlabeled FEDAA (B). Specific binding was indicated as the
difference between the two values. Data are representive of three
independent experiments that gave closely similar results. Scale bar
indicates 1 cm.
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Figure S2. Unlabeled FEDAA-1106 displaced 18F-FEDAA1106 from the murine heart. 18F-FEDAA1106 was introduced systemically into ApoE2/2
mice, and PET imaging was performed. A, The data shown were acquired for 5 minutes (from 115 to 120 minutes following injection of 18F-
FEDAA) in the absence of unlabeled FEDAA1106. B, Unlabeled FEDAA1106 (2.6 mg/kg [250 nmol injected]) was introduced at 120 minutes after
injection of 18F-FEDAA1106. The data shown were acquired for 5 minutes (from 25 to 30 minutes following injection of unlabeled FEDAA1106;
145 to 150 minutes after injection of 18F-FEDAA). Representative PET images are shown in sagittal orientation. Scale bar indicates 1 cm.
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